CARA caratherapeutics.com: שולי רווח נקי

Cara Therapeutics, Inc. (CARA) specializes in pruritus therapy, offering the unique drug Korsaiva for dialysis patients. The current net profit margin clearly demonstrates the business's financial stability, with 0.00 serving as the current level of this metric. While the company integrates its solutions into nephrology care, failed clinical trials have significantly weakened its commercial moats and market confidence.
Cara Therapeutics, Inc - פילוחים אנליטיים ומדדי מפתח (CARA)

The scale of Cara Therapeutics, Inc. (CARA) business is reflected in the dynamics of the net realization margin. This indicator determines the share of final profit within total revenue. The calculation captures the efficiency of converting sales into net income after deducting all expenses. A niche monopoly in the therapy of dialysis patients allows the company to maintain high pricing power. Long-term consensus links profitability growth to the absence of direct analogs for the flagship drug.